Prescription Medicines
Litazin Tab
- Product Category
- diabetes medication
- Active Ingredients
- Linagliptin
- Appearance
- Bright red, round, film-coated tablets
- Reimbursement Code
- 648104080
01 / 02
1. Composition and Strength : 1 tablet
- Active ingredient: Linagliptin (in-house specification) · · · · · · · 5.0mg
- Additives: Magnesium stearate, Opadry Pink (02F540025), corn starch, pregelatinized starch, hydroxypropyl cellulose, D-mannitol
2. Effectiveness
This drug is administered as an adjunct to diet and exercise therapy to improve blood sugar control in patients with type 2 diabetes.
- monotherapy
- Combination therapy
3. Dosage and dosage
The recommended dose of this drug is 5mg once a day.
Can be administered regardless of meal.
When administered concomitantly with insulin or insulin secretagogues (such as sulfonylureas), lower doses of insulin or insulin secretagogues may be necessary to minimize the risk of hypoglycemia.
4. Precautions for use
1. Do not administer to the following patients:
1) Patients with hypersensitivity to the main ingredient or other ingredients of this drug
2) Patients with type 1 diabetes or diabetic ketoacidosis
2. Administer with caution to the following patients:
1) Patients taking concomitant medication with drugs known to cause hypoglycemia: Insulin secretion stimulants such as insulin and sulfonylureas can cause hypoglycemia. When this drug was administered in combination with sulfonylurea, the rate of hypoglycemia was increased compared to placebo administered in combination with sulfonylurea. When this drug was administered in combination with insulin to patients with severe renal impairment, the incidence of hypoglycemia increased. Therefore, when administered in combination with this drug, lower doses of insulin and insulin secretagogues may be necessary to minimize the risk of hypoglycemia.
2) Heart failure: Since administration experience in patients with congestive heart failure is limited, it should be used with caution in these patients (see 12. Information for experts 1) Clinical trial information)
3) Pancreatitis: Acute pancreatitis has been observed in patients taking this drug. After discontinuation of linagliptin administration, improvement in pancreatitis was observed. Patients taking this medicine should be informed of the characteristic symptoms of acute pancreatitis (persistently severe abdominal pain), and if pancreatitis is suspected, taking this medicine should be discontinued.
4) Bullous-like pemphigus: Bullous-like pemphigus was observed in patients taking this drug. If bullous pemphigoid is suspected, this medication should be discontinued.
3. Adverse reactions
1) Monotherapy and combination therapy
The safety of this drug was evaluated in patients with type 2 diabetes who were administered 5 mg of this drug. In a placebo-controlled trial, 6,580 of 10,963 subjects were administered a therapeutic dose of 5 mg of linagliptin. Analysis of extracts from placebo-controlled trials showed that the overall adverse reaction rates in the placebo group and the linagliptin 5 mg group were similar (63.4% vs. 59.1%). The number of subjects who discontinued treatment due to adverse reactions was higher in the placebo group (4.3%) than in the linagliptin 5 mg group (3.4%). The most commonly reported adverse event was hypoglycemia, occurring in 22.9% of patients with the triple combination therapy of linagliptin, metformin, and sulfonylurea and in 14.8% of patients with placebo. In placebo-controlled clinical trials, hypoglycemia (10.9%, 471 people) was mild (80%, 384 people), moderate (16.6%, 78 people), or severe (1.9%, 9 people) depending on the severity. Adverse reactions reported in double-blind trials in which linagliptin 5 mg was administered as monotherapy, initial combination therapy, or additional combination therapy in clinical trials and adverse reactions confirmed in post-marketing experience are summarized in the table below (Table 1). For all adverse reactions, the frequency of occurrence is listed for each site of occurrence, and the following definitions are used for frequency; Very common (≥ 1/10), common (≥ 1/100 to <1/10), uncommon (≥ 1/1,000 to <1/100), rare (≥ 1/10,000 to <1/1,000), very rare (< 1/10,000), unknown (cannot be estimated from available data).
Table 1. Adverse reactions reported in subjects administered 5 mg per day of linagliptin alone or in additional combination therapy in clinical trials and adverse reactions identified in post-marketing experience
* Table: refer to manual
1? Adverse drug reactions based on post-marketing experience
2?Increase exceeding 3 times the upper limit of normal observed in clinical trials
3?According to the CAROLINA study (see clinical trial information section) comparing linagliptin and the active comparator glimepiride, laboratory analysis of amylase showed an increase exceeding 3 times the upper limit of normal in 0.99% of linagliptin patients and 0.54% of glimepiride patients.
4See Linagliptin Cardiovascular and Renal Safety Study (CARMELINA) (see Clinical Trial Information Section)
2) low blood sugar
In placebo-controlled clinical trials, 471 (10.9%) of the 4302 patients who received 5 mg of this drug reported hypoglycemia, while 275 (11.6%) of the 2364 patients in the placebo group reported hypoglycemia.
3) Laboratory tests
No significant differences were observed in laboratory values when comparing the drug-treated group and the placebo-treated group. As a laboratory test result that occurred more frequently than 1%, uric acid was observed to increase by 1.3% in the placebo group and by 2.7% in the test group.
Linagliptin Cardiovascular and Renal Safety Study (CARMELINA)
The CARMELINA study investigated the cardiovascular and renal safety of linagliptin compared to placebo in patients with type 2 diabetes at high cardiovascular risk based on underlying macrovascular or renal disease (see Section 12. Information for Experts). The study included 3494 patients receiving linagliptin (5 mg) and 3485 patients receiving placebo. Treatment with this drug did not increase the risk of major cardiovascular events, hospitalization for heart failure, or renal outcomes. The incidence of total and serious adverse events in patients receiving linagliptin was similar to that in patients receiving placebo.
In the treatment group, severe cases of hypoglycemia were reported in 3.0% of patients receiving this drug and 3.1% of patients receiving placebo. The incidence of severe hypoglycemia in patients treated with sulfonylurea at baseline was 2.0% in the drug-treated group and 1.7% in the placebo-treated group. In patients taking insulin at baseline, the incidence of severe hypoglycemia was 4.4% in the drug-treated group and 4.9% in the placebo-treated group.
During the entire study observation period, a diagnosis of acute pancreatitis was reported in 0.3% of patients receiving this drug and 0.1% of patients receiving placebo.
Bullous-like pemphigoid was reported in 0.2% of patients treated with this drug and was not reported in the placebo group.
4) As a result of analyzing domestic voluntary adverse event reporting data (1989-2014), the adverse events reported in statistically significantly higher numbers compared to adverse events occurring in other pharmaceutical products for which adverse events were reported were as follows. However, this does not mean that the causal relationship between the relevant ingredient and the following adverse events has been proven.
- Digestive system: Indigestion
- Abnormalities in the entire body and administration site: edema, facial edema, peripheral edema
5) As a result of analysis and evaluation of clue information based on domestic post-marketing adverse event reporting data (1989-2015), the newly confirmed adverse cases are as follows. However, this does not mean that the causal relationship between the relevant ingredient and the following adverse events has been proven.
- Metabolism and nutritional system: weight loss
- Mental system: Increased appetite
6) Domestic post-marketing survey results
As a result of a post-marketing survey conducted on 3,119 people over 6 years for re-examination in Korea, the occurrence rate of adverse events was reported to be 7.69% (240/3,119 people, 313 cases in total) regardless of causal relationship. Among these, serious adverse events unrelated to a causal relationship and serious adverse drug reactions for which a causal relationship cannot be ruled out are listed in the table below according to the frequency of occurrence.
* Table: refer to manual
In addition, unexpected adverse events unrelated to causal relationships and unexpected adverse drug reactions for which causal relationships cannot be ruled out are listed in the following table according to the frequency of occurrence.
* Table: refer to manual
4. General precautions
1) Severe and disabling joint pain
Severe and disabling arthralgia have been reported in post-marketing studies in patients taking DPP-4 inhibitors. The onset of symptoms after drug administration varied from 1 day to several years later. Symptoms were alleviated when drug administration was stopped. In some patients, recurrence of symptoms occurred when taking the same drug or a different DPP-4 inhibitor. Consider the DPP-4 inhibitor as the cause of severe arthralgia and, if appropriate, discontinue administration.
2) Bullous pemphigoid
Bullous-like pemphigus requiring hospitalization has been reported in patients taking DPP-4 inhibitors. Patients generally recovered with discontinuation of DPP-4 inhibitors and treatment with topical or systemic immunosuppressants. Patients should be advised to immediately report to their doctor if blisters or sores occur while taking this medication. If bullous pemphigus is suspected, this medicine should be discontinued and a dermatologist should be consulted for diagnosis and appropriate treatment.
5. Interaction
1) In-vitro evaluation of drug interactions
This drug is a weak to moderate inhibitor of CYP3A4, but does not inhibit or induce other CYP isoenzymes. This drug is a substrate of P-glycoprotein and weakly inhibits the transport of digoxin by P-glycoprotein. Based on these results and in-vivo drug interaction studies, this drug is not considered to interact with other P-gp substrates.
2) In-vivo evaluation of drug interactions
According to the clinical data described below, no clinically significant interactions requiring dose adjustment were observed when administered with other medicines. This drug did not show clinically significant effects on the pharmacokinetics of metformin, glibenclamide, simvastatin, pioglitazone, warfarin, digoxin, or oral contraceptives, and is therefore considered to have a low tendency to cause drug interactions with substrates of CYP3A4, CYP2C9, CYP2C8, P-glycoprotein, and organic cationic transporter (OCT).
3) Metformin: When 850 mg of metformin was administered multiple times three times a day to healthy subjects and 10 mg of linagliptin (high therapeutic dose) was co-administered once a day, there was no clinically significant change in the pharmacokinetics of linagliptin or metformin.
4) Sulfonylurea: When 1.75 mg of glibenclamide (glyburide) was administered as a single dose and 5 mg of linagliptin was administered orally multiple times, there was no change in the pharmacokinetics of 5 mg of linagliptin. However, there was a 14% decrease in AUC and Cmax. Clinically significant interactions are not expected with other sulfonylurea agents that are eliminated by CYP2C9 like glibenclamide (e.g., glipizide, tolbutamide, and glimepiride).
5) Thiazolidinedione: When pioglitazone, a substrate of CYP2C8 and CYP3A4, was administered multiple times at a daily dose of 45 mg and linagliptin 10 mg (high therapeutic dose) was administered multiple times, there was no clinically relevant effect on the pharmacokinetics of linagliptin or pioglitazone or the effective metabolite of pioglitazone.
6) Ritonavir: A study was conducted to evaluate the effect of ritonavir, a strong inhibitor of P-glycoprotein and CYP3A4, on the pharmacokinetics of linagliptin. When linagliptin 5 mg was administered orally as a single dose and ritonavir 200 mg was coadministered multiple times, the AUC and Cmax of linagliptin increased by 2-fold and 3-fold, respectively. These changes in the pharmacokinetics of linagliptin are not considered clinically relevant. Therefore, clinically relevant interactions with other P-glycoprotein/CYP3A4 inhibitors are unlikely to occur and no dosage adjustments are required.
7) Rifampicin: A study was conducted to evaluate the effect of rifampicin, a strong inducer of P-glycoprotein and CYP3A4, on the pharmacokinetics of linagliptin 5 mg. As a result of multiple co-administration of linagliptin and rifampicin, the AUC and Cmax of linagliptin decreased by 39.6% and 43.8%, respectively, and DPP-4 inhibition at the trough decreased by about 30%. Therefore, when linagliptin is administered in combination with a strong P-gp inducer, it is expected to be clinically effective, but it will not show sufficient effectiveness.
8) Digoxin: When the daily dose of 5 mg of linagliptin and 0.25 mg of digoxin were administered multiple times to healthy volunteers, there was no effect on the pharmacokinetics of digoxin.
9) Warfarin: When linagliptin was administered multiple times at a daily dose of 5 mg, it did not change the pharmacokinetics of S(-) or R(+) warfarin, which are CYP2C9 substrates.
10) Simvastatin: When 10 mg of linagliptin and 40 mg of simvastatin were administered together to healthy volunteers for 6 days, the plasma AUC of simvastatin increased by 34% and the plasma Cmax increased by 10%. Because linagliptin weakly inhibits CYP3A4-mediated metabolism, dose adjustment is not considered necessary when substrates metabolized by CYP3A4 are administered simultaneously.
11) Oral contraceptives: When 5 mg of linagliptin was coadministered with levonorgestrel or ethinyl estradiol, there was no change in their pharmacokinetic steady state.
6. Administration to pregnant and lactating women
1) Pregnant women: There are no controlled test results for pregnant women, so use in pregnant women is not recommended. In animal experiments, no adverse reactions to fertility were observed when the highest dose of 240 mg/kg/day (approximately 943 times the human exposure according to AUC comparison) was administered.
When administered orally to pregnant rats and rabbits, linagliptin passed through the placenta to the fetus.
2)Nursing mothers: In animal experiments, linagliptin and its metabolites were observed to be excreted through breast milk. It is not known whether this drug is excreted in human milk. Caution should be exercised when administering this drug to nursing mothers.
7. Administration to children
Safety and efficacy in pediatric patients 10 to 17 years of age have not been established in clinical trials.
This drug has not been studied in pediatric patients younger than 10 years of age.
Therefore, administration of this drug to pediatric and adolescent patients is not recommended.
Linagliptin was administered to children and adolescents aged 10 to 17 years with type 2 diabetes for up to 52 weeks. The safety profile of linagliptin was similar to that in the adult population.
8. Administration to elderly people
Among the patients (total of 4,040 people) who participated in the clinical trials of this drug, 1,085 patients were 65 years or older and 131 patients were 75 years or older. Safety effectiveness in elderly patients was no different from that in younger patients. Dosage adjustment in elderly people is not necessary.
9. Administration to patients with renal and hepatic impairment
No dosage adjustment is required when administering to patients with renal or hepatic dysfunction.
10. Treatment in case of overdose
1) In a control test conducted on healthy subjects, linagliptin was well tolerated even when administered at a maximum of 600 mg (120 times the recommended dose). There is no experience administering more than 600 mg to humans.
2) If an overdose is administered, it is reasonable to provide general supportive care. For example, remove unabsorbed substances from the gastrointestinal tract, monitor clinical symptoms, and take clinical action when necessary.
11. Storage and handling precautions
1) Keep out of reach of children.
2) Be careful as changing it into another container may cause an accident or is undesirable in terms of maintaining quality.
12. Pharmaceutical equivalence test information
A. The test drug Linagliptin tablets 5 mg (KyungDong Pharm Co., Ltd.) and the control drug Trajenta tablets (linagliptin) (Korea Boehringer Ingelheim Co., Ltd.) were administered once orally to healthy adults as a single tablet each in a 2x2 crossover test. As a result, blood linagliptin was measured in 47 people. When the comparative evaluation item values (AUCt, Cmax) were log-transformed and statistically processed, the average value was The 90% confidence interval of the difference was within log0.8 to log1.25, proving biological equivalence.
* Table: refer to manual
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 tablets/bottle
7. Period of use
36 months from date of manufacture
- Active ingredient: Linagliptin (in-house specification) · · · · · · · 5.0mg
- Additives: Magnesium stearate, Opadry Pink (02F540025), corn starch, pregelatinized starch, hydroxypropyl cellulose, D-mannitol
2. Effectiveness
This drug is administered as an adjunct to diet and exercise therapy to improve blood sugar control in patients with type 2 diabetes.
- monotherapy
- Combination therapy
3. Dosage and dosage
The recommended dose of this drug is 5mg once a day.
Can be administered regardless of meal.
When administered concomitantly with insulin or insulin secretagogues (such as sulfonylureas), lower doses of insulin or insulin secretagogues may be necessary to minimize the risk of hypoglycemia.
4. Precautions for use
1. Do not administer to the following patients:
1) Patients with hypersensitivity to the main ingredient or other ingredients of this drug
2) Patients with type 1 diabetes or diabetic ketoacidosis
2. Administer with caution to the following patients:
1) Patients taking concomitant medication with drugs known to cause hypoglycemia: Insulin secretion stimulants such as insulin and sulfonylureas can cause hypoglycemia. When this drug was administered in combination with sulfonylurea, the rate of hypoglycemia was increased compared to placebo administered in combination with sulfonylurea. When this drug was administered in combination with insulin to patients with severe renal impairment, the incidence of hypoglycemia increased. Therefore, when administered in combination with this drug, lower doses of insulin and insulin secretagogues may be necessary to minimize the risk of hypoglycemia.
2) Heart failure: Since administration experience in patients with congestive heart failure is limited, it should be used with caution in these patients (see 12. Information for experts 1) Clinical trial information)
3) Pancreatitis: Acute pancreatitis has been observed in patients taking this drug. After discontinuation of linagliptin administration, improvement in pancreatitis was observed. Patients taking this medicine should be informed of the characteristic symptoms of acute pancreatitis (persistently severe abdominal pain), and if pancreatitis is suspected, taking this medicine should be discontinued.
4) Bullous-like pemphigus: Bullous-like pemphigus was observed in patients taking this drug. If bullous pemphigoid is suspected, this medication should be discontinued.
3. Adverse reactions
1) Monotherapy and combination therapy
The safety of this drug was evaluated in patients with type 2 diabetes who were administered 5 mg of this drug. In a placebo-controlled trial, 6,580 of 10,963 subjects were administered a therapeutic dose of 5 mg of linagliptin. Analysis of extracts from placebo-controlled trials showed that the overall adverse reaction rates in the placebo group and the linagliptin 5 mg group were similar (63.4% vs. 59.1%). The number of subjects who discontinued treatment due to adverse reactions was higher in the placebo group (4.3%) than in the linagliptin 5 mg group (3.4%). The most commonly reported adverse event was hypoglycemia, occurring in 22.9% of patients with the triple combination therapy of linagliptin, metformin, and sulfonylurea and in 14.8% of patients with placebo. In placebo-controlled clinical trials, hypoglycemia (10.9%, 471 people) was mild (80%, 384 people), moderate (16.6%, 78 people), or severe (1.9%, 9 people) depending on the severity. Adverse reactions reported in double-blind trials in which linagliptin 5 mg was administered as monotherapy, initial combination therapy, or additional combination therapy in clinical trials and adverse reactions confirmed in post-marketing experience are summarized in the table below (Table 1). For all adverse reactions, the frequency of occurrence is listed for each site of occurrence, and the following definitions are used for frequency; Very common (≥ 1/10), common (≥ 1/100 to <1/10), uncommon (≥ 1/1,000 to <1/100), rare (≥ 1/10,000 to <1/1,000), very rare (< 1/10,000), unknown (cannot be estimated from available data).
Table 1. Adverse reactions reported in subjects administered 5 mg per day of linagliptin alone or in additional combination therapy in clinical trials and adverse reactions identified in post-marketing experience
* Table: refer to manual
1? Adverse drug reactions based on post-marketing experience
2?Increase exceeding 3 times the upper limit of normal observed in clinical trials
3?According to the CAROLINA study (see clinical trial information section) comparing linagliptin and the active comparator glimepiride, laboratory analysis of amylase showed an increase exceeding 3 times the upper limit of normal in 0.99% of linagliptin patients and 0.54% of glimepiride patients.
4See Linagliptin Cardiovascular and Renal Safety Study (CARMELINA) (see Clinical Trial Information Section)
2) low blood sugar
In placebo-controlled clinical trials, 471 (10.9%) of the 4302 patients who received 5 mg of this drug reported hypoglycemia, while 275 (11.6%) of the 2364 patients in the placebo group reported hypoglycemia.
3) Laboratory tests
No significant differences were observed in laboratory values when comparing the drug-treated group and the placebo-treated group. As a laboratory test result that occurred more frequently than 1%, uric acid was observed to increase by 1.3% in the placebo group and by 2.7% in the test group.
Linagliptin Cardiovascular and Renal Safety Study (CARMELINA)
The CARMELINA study investigated the cardiovascular and renal safety of linagliptin compared to placebo in patients with type 2 diabetes at high cardiovascular risk based on underlying macrovascular or renal disease (see Section 12. Information for Experts). The study included 3494 patients receiving linagliptin (5 mg) and 3485 patients receiving placebo. Treatment with this drug did not increase the risk of major cardiovascular events, hospitalization for heart failure, or renal outcomes. The incidence of total and serious adverse events in patients receiving linagliptin was similar to that in patients receiving placebo.
In the treatment group, severe cases of hypoglycemia were reported in 3.0% of patients receiving this drug and 3.1% of patients receiving placebo. The incidence of severe hypoglycemia in patients treated with sulfonylurea at baseline was 2.0% in the drug-treated group and 1.7% in the placebo-treated group. In patients taking insulin at baseline, the incidence of severe hypoglycemia was 4.4% in the drug-treated group and 4.9% in the placebo-treated group.
During the entire study observation period, a diagnosis of acute pancreatitis was reported in 0.3% of patients receiving this drug and 0.1% of patients receiving placebo.
Bullous-like pemphigoid was reported in 0.2% of patients treated with this drug and was not reported in the placebo group.
4) As a result of analyzing domestic voluntary adverse event reporting data (1989-2014), the adverse events reported in statistically significantly higher numbers compared to adverse events occurring in other pharmaceutical products for which adverse events were reported were as follows. However, this does not mean that the causal relationship between the relevant ingredient and the following adverse events has been proven.
- Digestive system: Indigestion
- Abnormalities in the entire body and administration site: edema, facial edema, peripheral edema
5) As a result of analysis and evaluation of clue information based on domestic post-marketing adverse event reporting data (1989-2015), the newly confirmed adverse cases are as follows. However, this does not mean that the causal relationship between the relevant ingredient and the following adverse events has been proven.
- Metabolism and nutritional system: weight loss
- Mental system: Increased appetite
6) Domestic post-marketing survey results
As a result of a post-marketing survey conducted on 3,119 people over 6 years for re-examination in Korea, the occurrence rate of adverse events was reported to be 7.69% (240/3,119 people, 313 cases in total) regardless of causal relationship. Among these, serious adverse events unrelated to a causal relationship and serious adverse drug reactions for which a causal relationship cannot be ruled out are listed in the table below according to the frequency of occurrence.
* Table: refer to manual
In addition, unexpected adverse events unrelated to causal relationships and unexpected adverse drug reactions for which causal relationships cannot be ruled out are listed in the following table according to the frequency of occurrence.
* Table: refer to manual
4. General precautions
1) Severe and disabling joint pain
Severe and disabling arthralgia have been reported in post-marketing studies in patients taking DPP-4 inhibitors. The onset of symptoms after drug administration varied from 1 day to several years later. Symptoms were alleviated when drug administration was stopped. In some patients, recurrence of symptoms occurred when taking the same drug or a different DPP-4 inhibitor. Consider the DPP-4 inhibitor as the cause of severe arthralgia and, if appropriate, discontinue administration.
2) Bullous pemphigoid
Bullous-like pemphigus requiring hospitalization has been reported in patients taking DPP-4 inhibitors. Patients generally recovered with discontinuation of DPP-4 inhibitors and treatment with topical or systemic immunosuppressants. Patients should be advised to immediately report to their doctor if blisters or sores occur while taking this medication. If bullous pemphigus is suspected, this medicine should be discontinued and a dermatologist should be consulted for diagnosis and appropriate treatment.
5. Interaction
1) In-vitro evaluation of drug interactions
This drug is a weak to moderate inhibitor of CYP3A4, but does not inhibit or induce other CYP isoenzymes. This drug is a substrate of P-glycoprotein and weakly inhibits the transport of digoxin by P-glycoprotein. Based on these results and in-vivo drug interaction studies, this drug is not considered to interact with other P-gp substrates.
2) In-vivo evaluation of drug interactions
According to the clinical data described below, no clinically significant interactions requiring dose adjustment were observed when administered with other medicines. This drug did not show clinically significant effects on the pharmacokinetics of metformin, glibenclamide, simvastatin, pioglitazone, warfarin, digoxin, or oral contraceptives, and is therefore considered to have a low tendency to cause drug interactions with substrates of CYP3A4, CYP2C9, CYP2C8, P-glycoprotein, and organic cationic transporter (OCT).
3) Metformin: When 850 mg of metformin was administered multiple times three times a day to healthy subjects and 10 mg of linagliptin (high therapeutic dose) was co-administered once a day, there was no clinically significant change in the pharmacokinetics of linagliptin or metformin.
4) Sulfonylurea: When 1.75 mg of glibenclamide (glyburide) was administered as a single dose and 5 mg of linagliptin was administered orally multiple times, there was no change in the pharmacokinetics of 5 mg of linagliptin. However, there was a 14% decrease in AUC and Cmax. Clinically significant interactions are not expected with other sulfonylurea agents that are eliminated by CYP2C9 like glibenclamide (e.g., glipizide, tolbutamide, and glimepiride).
5) Thiazolidinedione: When pioglitazone, a substrate of CYP2C8 and CYP3A4, was administered multiple times at a daily dose of 45 mg and linagliptin 10 mg (high therapeutic dose) was administered multiple times, there was no clinically relevant effect on the pharmacokinetics of linagliptin or pioglitazone or the effective metabolite of pioglitazone.
6) Ritonavir: A study was conducted to evaluate the effect of ritonavir, a strong inhibitor of P-glycoprotein and CYP3A4, on the pharmacokinetics of linagliptin. When linagliptin 5 mg was administered orally as a single dose and ritonavir 200 mg was coadministered multiple times, the AUC and Cmax of linagliptin increased by 2-fold and 3-fold, respectively. These changes in the pharmacokinetics of linagliptin are not considered clinically relevant. Therefore, clinically relevant interactions with other P-glycoprotein/CYP3A4 inhibitors are unlikely to occur and no dosage adjustments are required.
7) Rifampicin: A study was conducted to evaluate the effect of rifampicin, a strong inducer of P-glycoprotein and CYP3A4, on the pharmacokinetics of linagliptin 5 mg. As a result of multiple co-administration of linagliptin and rifampicin, the AUC and Cmax of linagliptin decreased by 39.6% and 43.8%, respectively, and DPP-4 inhibition at the trough decreased by about 30%. Therefore, when linagliptin is administered in combination with a strong P-gp inducer, it is expected to be clinically effective, but it will not show sufficient effectiveness.
8) Digoxin: When the daily dose of 5 mg of linagliptin and 0.25 mg of digoxin were administered multiple times to healthy volunteers, there was no effect on the pharmacokinetics of digoxin.
9) Warfarin: When linagliptin was administered multiple times at a daily dose of 5 mg, it did not change the pharmacokinetics of S(-) or R(+) warfarin, which are CYP2C9 substrates.
10) Simvastatin: When 10 mg of linagliptin and 40 mg of simvastatin were administered together to healthy volunteers for 6 days, the plasma AUC of simvastatin increased by 34% and the plasma Cmax increased by 10%. Because linagliptin weakly inhibits CYP3A4-mediated metabolism, dose adjustment is not considered necessary when substrates metabolized by CYP3A4 are administered simultaneously.
11) Oral contraceptives: When 5 mg of linagliptin was coadministered with levonorgestrel or ethinyl estradiol, there was no change in their pharmacokinetic steady state.
6. Administration to pregnant and lactating women
1) Pregnant women: There are no controlled test results for pregnant women, so use in pregnant women is not recommended. In animal experiments, no adverse reactions to fertility were observed when the highest dose of 240 mg/kg/day (approximately 943 times the human exposure according to AUC comparison) was administered.
When administered orally to pregnant rats and rabbits, linagliptin passed through the placenta to the fetus.
2)Nursing mothers: In animal experiments, linagliptin and its metabolites were observed to be excreted through breast milk. It is not known whether this drug is excreted in human milk. Caution should be exercised when administering this drug to nursing mothers.
7. Administration to children
Safety and efficacy in pediatric patients 10 to 17 years of age have not been established in clinical trials.
This drug has not been studied in pediatric patients younger than 10 years of age.
Therefore, administration of this drug to pediatric and adolescent patients is not recommended.
Linagliptin was administered to children and adolescents aged 10 to 17 years with type 2 diabetes for up to 52 weeks. The safety profile of linagliptin was similar to that in the adult population.
8. Administration to elderly people
Among the patients (total of 4,040 people) who participated in the clinical trials of this drug, 1,085 patients were 65 years or older and 131 patients were 75 years or older. Safety effectiveness in elderly patients was no different from that in younger patients. Dosage adjustment in elderly people is not necessary.
9. Administration to patients with renal and hepatic impairment
No dosage adjustment is required when administering to patients with renal or hepatic dysfunction.
10. Treatment in case of overdose
1) In a control test conducted on healthy subjects, linagliptin was well tolerated even when administered at a maximum of 600 mg (120 times the recommended dose). There is no experience administering more than 600 mg to humans.
2) If an overdose is administered, it is reasonable to provide general supportive care. For example, remove unabsorbed substances from the gastrointestinal tract, monitor clinical symptoms, and take clinical action when necessary.
11. Storage and handling precautions
1) Keep out of reach of children.
2) Be careful as changing it into another container may cause an accident or is undesirable in terms of maintaining quality.
12. Pharmaceutical equivalence test information
A. The test drug Linagliptin tablets 5 mg (KyungDong Pharm Co., Ltd.) and the control drug Trajenta tablets (linagliptin) (Korea Boehringer Ingelheim Co., Ltd.) were administered once orally to healthy adults as a single tablet each in a 2x2 crossover test. As a result, blood linagliptin was measured in 47 people. When the comparative evaluation item values (AUCt, Cmax) were log-transformed and statistically processed, the average value was The 90% confidence interval of the difference was within log0.8 to log1.25, proving biological equivalence.
* Table: refer to manual
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 tablets/bottle
7. Period of use
36 months from date of manufacture
Product Updates
Total 1items
| No. | Product Name | Details | Date of Change | Download |
|---|---|---|---|---|
| 1 | Litazin Tab | Precautions for use | 2025.05.12 | PDFLinagliptin single agent (film-coated tablet) unified adjustment (draft) (precautions for use)....pdf |